Immunohistochemistry (IHC) is a tool for visualizing protein expression that is employed as part of the diagnostic workup for the majority of solid tissue malignancies. Existing IHC methods use antibodies tagged with fluorophores or enzyme reporters that generate colored pigments. Because these reporters exhibit spectral and spatial overlap when used simultaneously, multiplexed IHC is not routinely used in clinical settings. We have developed a method that uses secondary ion mass spectrometry to image antibodies tagged with isotopically pure elemental metal reporters. Multiplexed ion beam imaging (MIBI) is capable of analyzing up to 100 targets simultaneously over a five-log dynamic range. Here, we used MIBI to analyze formalin-fixed, paraffin-embedded human breast tumor tissue sections stained with ten labels simultaneously. The resulting data suggest that MIBI can provide new insights into disease pathogenesis that will be valuable for basic research, drug discovery and clinical diagnostics.
Antibodies were first employed in tissue section analysis in 1942 to visualize pneumococcal antigens in organ biopsies from mice infused with live bacteria 1 . Since that time, IHC has become a mainstay of clinical diagnostics and basic research and is primarily used to assess the spatial distribution of one or two (rarely more) antigens in tissue sections. Despite the high specificity of many antibodies, the concentration of most antigens is insufficient to permit detection by conventional assays without signal amplification [2] [3] [4] . Signal amplification is typically achieved by using multivalent enzymelinked secondary antibodies that bind the Fc portion of the primary antibody. In brightfield microscopy, the most commonly used enzymatic reporter is horseradish peroxidase, typically used to oxidize 3,3′-diaminobenzidine (DAB), resulting in accumulation of a brown precipitate. Such nonlinear enzymatic amplification can result in poor correlation with the target antigen concentration 2, 5 .
Simultaneous detection of multiple antigens is subject to additional constraints that limit the utility of existing IHC-based analysis for predictive biomarker development in human clinical trials and clinical diagnostics. Colorimetric detection of four antigens has been reported using multiple enzyme-linked secondary antibodies, but in practice, this approach is usually limited to two because of difficulties encountered in sample preparation and imaging 2, 6 . Fluorescent labels used in the related immunofluorescence technique provide a higher signal-to-noise ratio and are more frequently used for simultaneous detection of multiple targets. Practical limitations include the need for primary antibodies generated in dissimilar host species and for nonoverlapping reporter emission spectra 5 . Thus, conventional IHC or immunofluorescence methodologies do not support the robust generation of quantitative multiplexed data needed to understand the relationship between tissue microarchitecture and expression at a subcellular level.
Previous work by our lab and others has demonstrated the utility of elemental mass spectrometry in circumventing similar limitations encountered in fluorescence-based flow cytometry [7] [8] [9] [10] [11] . In this approach, termed mass cytometry, cells stained with antibodies carrying isotopically pure nonbiological elemental metal reporters are nebulized into single-cell droplets before sequential analysis via inductively coupled plasma time-of-flight mass spectrometry. In principle, single-cell analysis of up to 100 parameters can be achieved without spectral overlap between channels 11 .
Here, we present a modality that uses secondary ion mass spectrometry to image metal isotope-carrying antibodies. MIBI is capable of analyzing samples stained simultaneously with up to 100 metal isotope-labeled antibodies and is compatible with standard formalinfixed, paraffin-embedded (FFPE) tissue sections, the most common type of specimen in clinical repositories worldwide 12 . Depending on the element of interest, MIBI can achieve as low as parts-per-billion sensitivity over a five-log dynamic range at resolutions comparable to those achieved with high-magnification light microscopy [13] [14] [15] [16] . We used MIBI to image breast tumor tissue sections stained with clinically relevant metal-conjugated antibodies. The data generated from these experiments can be interpreted within a conventional imaging context and by using high-dimensional analytics that reveal hidden phenotypic and morphological features of each biopsy.
reagents, biological specimens are incubated with primary antibodies coupled to stable lanthanides that are highly enriched for a single isotope (Fig. 1) . Primary antibodies are combined in solution for simultaneous incubation with the specimen. The specimens prepared for MIBI are mounted in a sample holder and subjected to a rasterized oxygen duoplasmatron primary ion beam. As this ion beam strikes the sample, lanthanide adducts of the bound antibodies are liberated as secondary ions. In this study, we subsequently analyzed the secondary ions via a magnetic sector mass spectrometer equipped with multiple detectors, permitting parallel detection of multiple lanthanide isotopes (mass-based reporters). The resultant data produced a two-dimensional map of the elemental distribution of each lanthanide and thus each antibody and its corresponding epitope.
As part of preliminary validation studies, we assessed peripheral blood mononuclear cells (PBMCs) stained with seven metal isotope-conjugated primary antibodies to CD3, CD4, CD8, CD14, CD19, CD45 and human leukocyte antigen-DR (HLA-DR) in parallel using mass cytometry and MIBI (Fig. 2) . We performed mass cytometry on the PBMC suspension as described previously 7 . For MIBI, cells were immobilized on a poly-l-lysine-coated silicon wafer, dried under vacuum and subsequently analyzed using a NanoSIMS 50L mass spectrometer. Sequential 50-µm fields were each scanned for 5 min (Fig. 2a) . We aligned 10-µm overlapping regions of each field to construct a composite mosaic using an automated script in Matlab. We segmented the resultant mosaic into single-cell regions of interest (ROIs) using the CD45 channel 17 . To extract single-cell expression data for each antibody, the ion count for each channel was integrated for each cell ROI. To achieve this mosaic, we imaged 1,200 fields for 5 min per field (99 h total scan time). However, as discussed below, orders-of-magnitude improvements in throughput can be achieved with appropriate sample preparation and instrumentation modifications.
Mass cytometry and MIBI produced comparable results and qualitative patterns of expression when analyzed via traditional biaxial plots (Fig. 2b) , with marker intensities determined by MIBI demonstrating a linear dynamic range spanning five orders of magnitude. Additionally, both platforms yielded quantitatively similar frequencies for seven manually gated cell populations (Fig. 2c) , with three of these populations differing by less than 1% between platforms (B cells, CD8 + T cells and CD4 + T cells). Altogether, using PBMCs as a test case, MIBI yielded results both qualitatively and quantitatively equivalent to those of a conventional analytical platform and also revealed spatial features of protein expression at the subcellular level.
Ten-color imaging of human breast tumor tissue sections In order to use MIBI for analysis of tissue sections acquired in a diagnostic setting, we sought to verify the performance of metal-conjugated versions of the antibodies by comparing the staining behavior of metal-conjugated versus unmodified primary antibodies using conventional immunoperoxidase chemistry. Secondary staining of serial sections from a single FFPE human breast tumor tissue block treated with metal-conjugated or unmodified primary antibodies for Ki-67 or estrogen receptor-α (ERα) demonstrated positive nuclear staining of comparable intensity and similar levels of background staining (Fig. 3a) , indicating that the metal conjugation did not materially affect specific and nonspecific staining behavior.
Finally, to assess the overall performance of MIBI in a diagnostic imaging application, we analyzed FFPE breast tumor tissue sections with different immunophenotypic profiles. We verified ERα, progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) positivity in a clinical IHC lab using validated reagents. For MIBI, we mounted tumor sections on poly-l-lysine-coated silicon wafers, deparaffinized them and subjected them to heat-induced epitope retrieval before overnight staining with metal-conjugated antibodies for double-stranded DNA (dsDNA), ERα, PR, E-cadherin, Ki-67, vimentin, actin, keratin and HER2. Conveniently, a hematoxylin counterstain can be readily detected by measuring its elemental aluminum content. The following day, the sections were washed, counterstained with hematoxylin and dehydrated via graded ethanol series. Figure 1 Workflow summary of MIBI. Biological specimens, such as FFPE tissue or cell suspensions, are immobilized on a conductive substrate, such as indium tin oxide-coated glass or silicon wafer. Samples are subsequently stained with antibodies conjugated to unique transition element isotope reporters, dried and loaded under vacuum for MIBI analysis. The sample surface is rasterized with an oxygen primary ion beam that sputters the antibody-specific isotope reporters native to the sample surface as secondary ions. Metal-conjugated antibodies are quantified via replicate scans of the same field of view, where up to seven metal reporters are measured with each scan, and the detectors are mass calibrated after each scan cycle. ROIs demarcating nuclear and cytosolic compartments of each cell are integrated, tabulated and categorized. Composite images comprised of pseudocolored categorical features and quantitative three-color overlays are constructed to summarize multidimensional expression data.
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Using the MIBI analysis, conventional high-resolution images can be generated using FFPE tissues. We acquired ten-marker images in two consecutive scans of the same 80-µm field of view, with each scan lasting 25 min. We acquired images for hematoxylin, ERα, PR, Ki-67, E-cadherin, HER2 and dsDNA during the first scan and keratin, vimentin and actin during the second. We constructed pseudobrightfield images mimicking traditional DAB staining by coding hematoxylin on a white-to-blue scale and putting the desired marker on a white-to-brown scale (Fig. 3b) . We also constructed pseudofluorescence images mimicking three-color immunofluorescence using a dsDNA channel (red), a hematoxylin channel (blue) and a marker channel (green) (Fig. 3b) . Pseudobrightfield and pseudofluorescence composites for each antibody within a single field of view for three tumor biopsies are shown in Figure 3c . Comparison of HER2, ERα and PR positivity across the three specimens demonstrated appropriate expression of each marker with respect to immunophenotypes established by conventional IHC staining. Sections expressing ERα and PR demonstrated well-demarcated nuclear staining, scattered Ki-67 + nuclei and intense positive staining for vimentin in mesenchymal cells. HER2 + sections demonstrated strong membrane staining. E-cadherin, actin and keratin also demonstrated appropriate subcellular staining patterns.
Image segmentation and feature extraction
In order to further explore the utility of the information inherent in the quantitatively multiplexed images in this study, we performed image segmentation so that cellular features could be analyzed and compared. We segmented hematoxylin and dsDNA channels for each tumor using CellProfiler in order to extract summary statistics describing subcellular expression 18, 19 (Fig. 4a) . The pixel intensity for each marker and subcellular ROI demonstrated distinctly different distributions with respect to the known immunophenotype of each tumor (Supplementary Fig. 1 ). We quantified mean pixel intensities for each marker within nuclear, cytoplasmic and cellular ROIs for each cell. Biaxial scatter plots demonstrated marker coexpression matching the known immunophenotype for each tumor (Fig. 4b) We further assessed quantitative accuracy by comparing MIBI to a US Food and Drug Administration (FDA)-approved quantitative image analysis (QIA) workflow for determining the staining intensity of scanned IHC tissue sections. We used QIA to quantify ERα nuclear expression in a cohort of nine breast tumors. We manually annotated tumor-containing regions and subsequently analyzed them using an automated algorithm optimized for determining immunoperoxidase nuclear staining intensity. The resultant data included mean intensity and an overall H-score (a scale for quantifying the intensity of expression of a protein in IHC staining). Linear regression analysis comparing mean ERα nuclear staining intensity by MIBI or IHC demonstrated robust agreement between the two methods (Fig. 4c , r = 0.99, P < 0.00001). We calculated cutoff points for MIBI staining intensity with the resultant linear equation (MIBI = 0.064 + 0.0073 × IHC) using the respective values for negative, 1+, 2+ and 3+ employed by QIA; we subsequently used these cutoff points to calculate an overall H-score. Linear regression analysis comparing IHC and MIBI H-scores also demonstrated strong robust agreement (Fig. 4c , r = 0.99, P < 0.00001) with a slope near unity (m = 1.06 ± 0.06 s.d.). The strong correlation between H-scores derived from each method suggests that MIBI not only captured the mean overall staining intensity but also was able to accurately capture the biological variability of ERα expression. This implies that the true distribution of staining intensity was valid and accurately recapitulated. These results also suggest that, at least within the context of its application here, MIBI analysis is not materially affected by sample-to-sample matrix effects that can arise when using a bioanalysis platform. Furthermore, comparison of ERα staining intensity in serial sections treated with all nine antibodies or only the ERα-specific antibody shows that the quantitative accuracy of this method is unaffected by multiplexing (Supplementary Fig. 2 ). npg Integrated histologic and immunophenotypic features of multidimensional MIBI data can be visualized by generating composite images that combine quantitative (continuous) cytoplasmic and categorical (positive or negative) nuclear expression patterns (Fig. 5) The distribution of single-cell staining intensity by MIBI as a function of the mean staining intensity by IHC is shown in a box-and-whisker plot. Lower and upper boundaries of each box are defined by the first and third quartiles, respectively. Whisker length is set to 1.5 times the interquartile range. Linear regression analysis comparing the mean intensities and H scores using the two methods are shown in the top and bottom graphs, respectively (r = 0.99, P < 0.0001, Student's t-test).
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DISCUSSION
In this study, we have presented and validated elemental mass-based multiplexed IHC analysis that circumvents the limitations associated with conventional staining methods reliant on optical absorbance or fluorescence signals. This method can be used on virtually any vacuum-compatible specimen, including FFPE tissue. FFPE tissue is the most common type of specimen, with an estimated 1 billion blocks stored in clinical repositories globally 11 . In validating this method, we were able to demonstrate an immunophenotypic analysis of PBMCs that is almost quantitatively identical to that attained using mass cytometry. Subsequent multiplexed analyses FFPE breast tumor biopsies produced staining patterns and intensities for each antigen that were equivalent to validated, single-plex immunoperoxidase assays used in clinical labs. Additionally, marker multiplexing and image segmentation permitted quantitative feature extraction describing cellular and subcellular expression, which, in aggregate, revealed immunophenotypes of cell subpopulations that could be related back to the original clinical pathology of the tissue. We demonstrated the quantitative accuracy of MIBI via side-by-side comparison with an FDA-approved QIA IHC platform. Lastly, new approaches in combinatorial false (or pseudo-) coloring were used to distill pertinent highdimensional features down to a rapidly interpretable image where multiple phenotypes are delineated using single colors.
MIBI has a number of advantages over conventional IHC techniques. Background signal due to autofluorescence is absent, and the five-log dynamic range presented here exceeds that of immunofluorescence and chromogenic IHC by 100-fold and 1,000-fold, respectively 2, 20, 21 . Because the mass accuracy can resolve less than a fraction of a dalton at even the lowest resolution (Supplementary Fig. 3) , no spectral overlap is observed between mass-adjacent elemental reporters. Moreover, the reporter panel can be designed such that neither residual isotopic contaminants (Supplementary Fig. 3 Figs. 4 and 5) interfere materially with the reporter masses associated with each antibody probe, obviating the need for channel compensation in the experiments herein. The assay's linearity is better than that of both chromogenic IHC and immunofluorescence because neither secondary labeling nor amplified detection are required 2 . As relatively conventional methods are used for immunoreactions and because mass tags do not degrade, samples are stable indefinitely, permitting remote preparation together with a centralized reading facility.
Immunofluorescence-based multiplexing assays have been reported previously. Multispectral imaging with careful selection of antibodies, secondary antibodies, fluorescent dyes and filter cubes can be used to achieve multiplexing of up to seven simultaneous labels, although such performance is rarely achieved and requires much optimization 22 . Sequential methods for multiplexing, sometimes referred to as dye cycling, have been described that use the general approach of repeated cycles of primary staining (with or without secondary staining), imaging and then quenching or bleaching or otherwise removing each cycle's fluorescent reporters. Methods for erasing the signals have included low-pH antibody elutions, high-temperature fluorophore denaturation, antibody stripping or photobleaching [23] [24] [25] [26] [27] [28] . These approaches have several shortcomings not found with MIBI. Some methods of dye cycling lead to accumulative structural changes that alter epitope antigenicity 23 . The techniques typically use just a few primary antibodies per round of staining, making the iterative methodology labor intensive and time consuming. Repeated processing of tissue sections can lead to altered histology that reduces the accuracy of image co-registration across staining cycles. In contrast, samples prepared for MIBI are stained with all antibodies in a single step. Markers are acquired in parallel in a single imaging session without any additional sample processing. Furthermore, histological stains, such as hematoxylin, are also detectable with this technique and can be overlaid with antibody expression data, making the representations created here indistinguishable from those of conventional IHC-based pathological analyses.
Other mass-based reporter systems have been used to image FFPE tissues previously 29 . These have taken two forms: matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) and laser-ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). MALDI-MS imaging, although adept at analyzing macromolecules, has inherent limitations owing to its requirement for a crystalline chemical matrix [30] [31] [32] . The matrix, combined with the instrument sensitivity, reduces achievable resolution (>5 µm) and obscures the signal from elemental reporters. LA-ICP-MS imaging, on the other hand, offers many of the same benefits as MIBI (for example, dynamic range and multiplexing of isotopic reporters). However, laser spot size and instrument sensitivity in previous studies have been limited in elemental reporter-based imaging assays. As such, imaging studies of FFPE breast carcinomas using commercially available LA-ICP-MS systems have yielded images with around 100-µm resolution 33 -a factor of nearly three orders of magnitude greater than the 200-to 300-nm resolution achieved in the analysis presented here. Taken together, the complexity, sensitivity and resolution of previously reported mass-based techniques limit their deployment in a clinical setting. npg One obstacle to broader application of MIBI is sample throughput. For antigens expressed at levels similar to those analyzed here, a 100-µm field of view for seven antibodies at a resolution comparable to that of light microscopy (200-300 nm) can be acquired in as little as 5 min. At this rate, a 500-µm field of view would require approximately 2 h to image. Larger numbers of antibodies could be acquired with repeat scans; however, this would increase the scan time proportionally. In future work, we expect to ameliorate the majority of these issues by employing newly developed primary ion beam sources and new instrument configurations. Next-generation oxygen ion sources with higher current densities and 50-nm beam spot sizes have recently become commercially available, theoretically permitting ~20-fold faster image acquisition than that of the current implementation described here 34 . This new ion beam source will provide lateral resolution comparable to that of confocal microscopy and axial resolution that exceeds confocal microscopy's 34 . Furthermore, new instrument configurations using a time-of-flight mass analyzer would permit parallel quantification of all mass reporters in a given experiment without a cyclic analysis. Taken together, gains from these achievable nextgeneration instrument configurations should reduce the acquisition time for 50-100 targets (mass reporters) in a 500-µm field of view to 5-10 min when imaged at resolutions equal to light microscopy.
In addition to instrument improvements, similar performance gains can be realized by increasing the amount of metal attached to each antibody. Current lanthanide metal antibody conjugation protocols achieve labeling efficiencies of 100-200 metal atoms per antibody 8 . The development of new nanoparticle-based reagents is projected to enable the attachment of up to 10,000 metal atoms per antibody. Such gains in labeling efficiency could further reduce scan times by as much as two orders of magnitude, such that a tumor microarray containing 1,000 600-µm core specimens could be imaged in as little as 1.5 h.
As a consequence of using antibodies for protein detection, MIBI inherits many of the issues that can limit the utility of conventional IHC. Poorly characterized reagents can exhibit nonspecific binding, and some epitopes are difficult to target with antibody-based approaches. However, we expect that reagents can be developed that will extend the capability of MIBI beyond antibody-based analysis to other arenas, such as in situ hybridization and subcellular metabolic analysis. These extended applications of MIBI, taken with the gains permitted by relatively minor modifications of existing analytical systems, introduce the prospect of a practical multiplexed imaging platform that integrates tissue histology, protein expression, gene expression and metabolism on a subcellular level. The basic science utility of such a system is evident, and clinical deployment of this technology would extend multiplexed expression analysis typically restricted to flow cytometry of cell suspensions (such as blood) to any solid tissue. Given the transformative effect that flow cytometry has shown in the diagnosis, staging and treatment of hematopoietic malignancies, the present approach, when applied to solid tissue samples, could provide new insight into disease pathogenesis, address pathway activation status, explore tumor heterogeneity and document effects of therapeutic interventions that could ultimately improve patient outcomes.
METHODS
Methods and any associated references are available in the online version of the paper. 
